THE ARISING · Longevity & Healthspan
Review Finds Weak Evidence That Olive Oil Products Protect Thinking
Olive oil has a reputation as a brain-friendly food, but a new systematic review of controlled human studies finds little firm proof that olive-derived products protect thinking in older age.
The review, published in Frontiers in Nutrition in 2026, systematically reviewed and narratively synthesized the available controlled clinical research on olive-derived products and cognition. It covered normal cognitive aging, mild cognitive impairment (MCI) and Alzheimer's disease. The authors searched PubMed, Web of Science and ClinicalTrials.gov and included 13 reports from 12 randomized groups.
Only three of those reports directly tested an olive-derived product. Three more studied extra-virgin olive oil as one part of a wider Mediterranean-diet program. The other seven used olive oil as the comparison for a different treatment, so they said little about olive oil itself.
The three direct trials found scattered differences. These appeared on a dementia rating scale called ADAS-Cog, on blood–brain barrier permeability, on functional connectivity (how brain regions work together) and on preservation of scores on the MMSE, a general cognitive screening test. According to the authors, the results were inconsistent across measures of overall thinking, specific mental skills, daily function and biological markers.
The Mediterranean-diet trials could not separate out the effect of olive oil from the rest of the diet. The trials that used olive oil as a comparison measured the effects of other treatments against olive-oil groups that varied from study to study.
The quality of the evidence was modest. No report was judged at low overall risk of bias. Three were rated high risk, and the other ten raised some concerns. Certainty in the evidence was low to very low for most direct and dietary-pattern results.
The authors stress that olive products are not one thing. Extra-virgin oil is rich in plant compounds called phenolics. Refined olive oil has far fewer of them. Olive-leaf preparations and isolated compounds differ again. The review argues these are often treated as interchangeable when they are not.
Biology gives reasons for interest. In worms and mice, olive compounds reduced Alzheimer's-type protein buildup and improved behavior, according to the review's introduction. Whether such effects occur in people at normal dietary amounts is not established.
Studies that follow people over time point in a similar direction, with mixed results. A separate study in Microbiome of 656 adults aged 55 to 75 with overweight or obesity and metabolic syndrome tied higher virgin olive oil intake to better cognitive scores over two years. Higher intake of common, refined-type olive oil was linked to faster decline. Those are associations from food questionnaires, and the authors of that study called for further high-quality research.
The review's authors conclude that selected studies show signals consistent with cognitive preservation, but these do not establish clinical efficacy for preventing or treating cognitive decline, MCI or Alzheimer's disease. For now, olive oil keeps its place as a staple of a well-regarded diet, while olive extracts lack trial evidence as dementia prevention.
The authors call for trials that define exactly what is in the olive product, enroll enough people, and set meaningful thinking and daily-function outcomes in advance. Those results are what to watch next.